Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG

Vaccine

Volumn 19, Issue 25-26, 2001, Pages 3485-3492

  Misra, Alka ^a   Dube, Anuradha ^a   Srivastava, Bindu ^a   Sharma, Preeti ^a   Srivastava, J K ^a   Katiyar, J C ^a   Naik, Sita ^b  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Alum precipitated autoclaved L. major; Indian langur monkey; Vaccination; Visceral leishmaniasis

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODY; BCG VACCINE; GAMMA INTERFERON; LEISHMANIA VACCINE;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; AUTOCLAVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; HUMAN; INDIA; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; MONKEY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRECIPITATION; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SPLEEN; VACCINATION; WORLD HEALTH ORGANIZATION;

ALUM COMPOUNDS; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BCG VACCINE; CERCOPITHECIDAE; CONCANAVALIN A; HUMANS; HYPERSENSITIVITY, DELAYED; INTERFERON TYPE II; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS, VISCERAL; LYMPHOCYTE ACTIVATION; MALE; PRECIPITATION; PROTOZOAN VACCINES; VACCINES, INACTIVATED;

EID: 0035858116     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00058-5     Document Type: Article

References (38)

1. Experiences with vaccines against cutaneous leishmaniasis: Of men and mice
2. Evidence that the high incidence of treatment failures in Indian kala-azar is due to emergence of antimony-resistant strains of Leishmania donovani
3. Immunological features of kala-azar
4. Cell-mediated immune response in Indian kala-azar and post kala-azar dermal leishmaniasis
5. Immunosuppression in Kenyan visceral leishmaniasis
6. Phytohaemagglutinine induced lymphocyte transformation test in Indian kala-azar
7. Characterization of in vitro proliferative responses of human lymphocytes to leishmanial antigens
8. Absence of gamma-interferon and interleukin-2 production during active visceral leishmaniasis
9. Suppression of IL-12 production by cryopreserved peripheral blood mono-nuclear cells from patients with active visceral leishmaniasis in Sicily
10. Protective effect of isoprinosine in genetically susceptible Balb/c mice infected with Leishmania major
11. Circulating factor from a kala-azar patient suppresses in vitro antileishmanial T cell proliferation
12. Cell mediated immunity in American cutaneous and mucosal leishmaniasis
13. Immunology of clinical and experimental leishmaniasis
14. Cutaneous leishmaniasis: The prospect for a killed vaccine
15. Vaccination: Past and future role in control
16. Vaccination and Immunological control of leishmaniasis
17. Development of vaccines against leishmaniasis
18. Vaccines against leishmaniasis
19. Stepwise safety trial of a killed leishmania vaccine in Iran
20. Vaccine for prophylaxis and immunotherapy, Brazil
21. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers
22. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population. Safety, immunogenicity, and efficacy during the first 12 months of follow-up
23. Randomized vaccines trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran
24. A randomised, double-blind controlled trial of a killed L. major plus BCG against zoonotic cutaneous leishmaniasis in Iran
25. Vaccination of Langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG
26. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120
27. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-I vaccine constructs: Granulocyte-macrophage colony-stimulating factor and TNF-α synergize with IL-12 to entance induction of cytotoxic T lymphocytes
28. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis
29. Protein measurement with folin-phenol reagent
30. Successful transmission of Leishmania donovani in Indian langurs (Presbytis entellus)
31. The Indian langur: Preliminary report of a new non-human primate host for visceral leishmaniasis
32. Leishmania donovani: Cellular and humoral immune responses in Indian langur monkeys, Presbytis entellus
33. A one stage procedure for isolation of granulocytes and lymphocytes from human blood
34. Natural and experimental re-infection of man with Oriental sore
35. Follow-up study of a vaccination programme against cutaneous leishmaniasis II. Vaccination with a recently isolated strain of L. tropica from Jericho
36. Controlled field trials of a vaccine against New World cutaneous leishmaniasis
37. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease